Alterations in gene expression associated with invasion of RAS-mutant thyroid tumors and their potential diagnostic and therapeutic utility
Authors:
- Vincenzo CondelloVCVincenzo Condello
- William R DoerflerWDWilliam R Doerfler
- Alyaksandr V NikitskiANAlyaksandr V Nikitski
- Daniel M SpagnoloDSDaniel M Spagnolo
- Ian J FornalIFIan J Fornal
- Gavin M SchmidtGSGavin M Schmidt
- Abigail I WaldAWAbigail I Wald
- Marina N NikiforovaMNMarina N Nikiforova
- Yuri E NikiforovYNYuri E Nikiforov
Open Access
- 29 May 2025
- journal article
- Published by Bioscientifica in European Thyroid Journal
- Vol. 14 (3)
Abstract
Introduction: Mutations of RAS genes are detected in a spectrum of follicular-patterned thyroid tumors. Preoperative prediction of invasive cancers based on the presence of RAS mutation alone is challenging because non-invasive and invasive tumors tend to have similar sonographic and cytologic features. The aim of this study was to perform clinicopathologic and molecular analyses of RAS-mutant tumors, identify molecular and clinical markers associated with invasiveness, and determine their diagnostic and therapeutic potentials. Methods: We collected clinicopathologic characteristics and performed RNA-seq on 48 surgically resected RAS-mutant thyroid tumors (23 non-invasive and 25 invasive). A classifier using expression data of selected invasiveness markers and clinical parameters was applied to an independent set of 54 RAS-mutant fine-needle aspiration (FNA) samples to predict invasion. Selected markers were investigated in vitro and in vivo. Results: On RNA-seq analysis, invasive RAS-mutant tumors showed different gene expression profiles compared to non-invasive tumors. Expression levels of six selected genes (CA12, CD44, LRP4, ECM1, FN1, and CRABP1) were associated with invasiveness on qRT-PCR. Expression levels of these genes plus nodule size predicted invasion in RAS-mutant FNA samples with 95% sensitivity and 89% specificity. siRNA silencing and chemical inhibition of CA12 reduced invasion of RAS-mutant human thyroid cells. Treatment of RAS-mutant xenografts with CA12 inhibitors arrested tumor growth. Conclusions: Development of invasion in RAS-mutant tumors is associated with significant alteration in gene expression. Expression levels of six genes and nodule size may predict invasion in RAS-mutant thyroid nodules, whereas chemical inhibition of CA12 may have a potential therapeutic effect in RAS-mutant tumors.Keywords
This publication has 61 references indexed in Scilit:
- Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles forBRAF, PIK3CA, andAKT1Cancer Research, 2009
- A Novel Complex BRAF Mutation Detected in a Solid Variant of Papillary Thyroid CarcinomaEndocrine Pathology, 2009
- Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomasOncogene, 2006
- Mutation of the PIK3CA Gene in Anaplastic Thyroid CancerCancer Research, 2005
- ECM1 and TMPRSS4 Are Diagnostic Markers of Malignant Thyroid Neoplasms and Improve the Accuracy of Fine Needle Aspiration BiopsyAnnals of Surgery, 2005
- Molecular Profile and Clinical-Pathologic Features of the Follicular Variant of Papillary Thyroid Carcinoma: An Unusually High Prevalence of ras MutationsAmerican Journal of Clinical Pathology, 2003
- RASPoint Mutations and PAX8-PPARγ Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2003
- Prevalence of Ras mutations in thyroid neoplasiaClinical Endocrinology, 1999
- Production of transgenic mice expressing the Ki-ras oncogene under the control of a thyroglobulin promoter.1993
- Index for rating diagnostic testsCancer, 1950